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Renal function is one of the most important prognostic factors in
patients with multiple myeloma (Durie and Salmon, 1975). During
the last 20 years myeloma treatment has changed substantially 
and now typically constitutes initial courses of infusional
chemotherapy (IC) with VAMP/C-VAMP/VAD (vincristine,
doxorubicin, and methylprednisolone or dexamethasone with or
without cyclophosphamide) followed in approximately 70% of
patients by consolidation with HDM and autologous stem cell
rescue with either cryopreserved marrow or peripheral blood stem
cells (Powles et al, 1997; Barlogie et al, 1999). Autotrans-
plantation is now considered for myeloma patients up to the age of
75 (Siegel et al, 2000, Sirohi et al, 2000) which implies that the
majority of patients with myeloma may benefit from this treat-
ment. Patients with renal dysfunction, however, are frequently
excluded from high dose protocols, even though the case for this
practice has been weakened since the French and Little Rock
groups have shown that renal insuffciency may not be a valid crite-
rion for exclusion from high-dose therapy programs (Kergueris 
et al, 1994; Tricot et al, 1996). 
We have previously reported that some patients who present
with renal dysfunction recover normal renal function after IC,
whereas others go on to develop renal dysfunction during IC
(Sirohi et al, 1999a). The purpose of the present observational
study was to assess whether renal function just prior to high-dose
treatment is of prognostic value with respect to treatment-related
toxicity, disease progression and survival. As measure of renal
function we used the glomerular filtration rate (GFR) corrected for
age, determined not more than 30 days prior to the HDM. All 
the 145 patients described here were treated uniformly with HDM
200 mg m–2. 
PATIENTS AND METHODS 
Patients 
From a prospectively maintained database, 145 newly diagnosed
patients with multiple myeloma who received HDM 200 mg m–2
as consolidation therapy were analysed. They presented to our unit
between August 1985 and June 1998. Written informed consent to
treatment was obtained according to institutional guidelines. 
Therapy 
Infusional chemotherapy (IC) 
Prior to the HDM, 144 patients were treated with infusional
chemotherapy (IC) with VAMP (n = 27), C-VAMP (n = 97) or V-
C-VAMP (n = 20) (vincristine, doxorubicin, methylprednisolone
with or without cyclophosphamide or verapamil; Forgeson et al,
1988; Raje et al, 1997a; Gore et al, 1988). All cycles were repeated
3 weekly until maximum response and followed by an additional
cycle. One patient received HDM with an autologous peripheral
stem cell graft at diagnosis. 
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Summary We correlated age and body surface area corrected glomerular filtration rate (GFR) at the time of high-dose melphalan (HDM)
administration with treatment-related toxicity (TT), time to disease progression and survival. Between 8/85 and 6/98, 144 newly diagnosed
myeloma patients with a median age of 53 years (range, 31–72) received infusional chemotherapy with vincristine, doxorubicin and
methylprednisolone, with/without cyclophosphamide or verapamil, followed by HDM 200 mg/m2 and stem cell rescue. An additional patient
received HDM at diagnosis. GFR was below normal in 38 patients (26%). At presentation, patients with low GFR at the time of HDM had
higher serum creatinine, β 2M, stage III disease, calcium and Bence–Jones proteinuria. Toxic deaths post-HDM were similar in both groups
(2/38 (5%) vs. 4/107 (4%)), though patients with low GFR had more oral mucositis (P < 0.0001), diarrhoea (P = 0.005) and infections (P =
0.04). The response and relapse rates of the 2 groups were not substantially different, but the median overall survival (OS) was significantly
shorter in patients with low GFR (5.1 vs 7.5 years, P = 0.015). Multivariate analysis showed that a normal GFR and being in CR at the time of
HDM were predictive of longer OS. We conclude that in context of high-dose chemotherapy for myeloma, dose of melphalan should not be
modified in patients with low GFR and that early intensive treatment at relapse may improve results in patients with abnormal renal function.
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All patients who were planned to receive HDM 6 weeks after the
last IC cycle had their GFR measured within 30 days before the
HDM and this was the most recent value. GFR was assessed by a
standard method using 51Cr EDTA as tracer (Brochner-Morteson,
1978) and corrected for body surface area (BSA) according to the
formula Corrected GFR = Measured GFR × 1.73 / BSA. 
Age-adjusted normal ranges were taken as: 
20–39 years: 87–135 ml min–1 1.73 m–2
40–49 years: 80–128 ml min–1 1.73 m–2
50–59 years: 75–124 ml min–1 1.73 m–2
< 60 years: 58–106 ml min–1 1.73 m–2
GFR was not routinely measured post HDM unless the patients
received a second course of high-dose therapy. 
A full blood count, clotting screen, serum biochemistry, para-
protein, immunoglobulin quantitation, β 2 M, urinary Bence–Jones
protein, bone marrow aspirate and trephine biopsy, chest X-ray,
electrocardiogram and, if indicated, MUGA scan, were carried out
just before the HDM. 
High-dose treatment 
Since the publication of the reports by the French and Little Rock
groups (Kergueris et al, 1994; Tricot et al, 1996) and after
approval by the institutional review board, HDM has been
included in the core care plan for patients with myeloma and 
renal impairment. All patients received melphalan at a dose of 
200 mg m–2 on day –1 as a bolus injection. Adequate hydration
was ensured to maintain a urine output of 20 ml min–1 during the
first hour post high dose and 500 ml h–1 in the subsequent 2 hours.
Patients received autologous bone marrow (n = 69) until
November 1992 (Cunningham et al, 1994). The marrow was
harvested 6 weeks after the last chemotherapy cycle. The target
mononuclear cell count was 2 to 5 × 108 cells kg–1 of body weight.
From December 1992 onwards peripheral blood stem cell trans-
plants (n = 76) were used. The G-CSF mobilization procedure
employed has been previously described (Powles et al, 1997; Raje
et al, 1997b). The stem cells were infused 24 hours after the
melphalan. 
All patients were admitted to a 4-bedded open ward on the first
day of conditioning and were nursed without barrier nursing. The
Hickman lines inserted for IC were removed before HDM and all
the patients received anti-pneumocystis carinii prophylaxis in the
form of nebulized Pentamidine 300 mg once a month (starting on
day –1). Packed red cells and platelets were transfused to keep the
Hb> 9 gm dl–1 and platelets > 10 × 109 l–1 (in afebrile patients, 
> 20 × 109 l–1 in febrile patients). Fluid and electrolyte balance was
strictly maintained throughout the period of hospitalization. Gut
sterilization was not used. Patients were commenced on empirical
antibiotic therapy according to the hospital guidelines if pyrexia 
> 38˚C occurred. Mouth care included chlorhexidine mouth
washes and nystatin suspension or amphotericin lozenges. A
normal diet was encouraged. None of the patients required renal
replacement therapy during the autotransplantation. 
Maintenance therapy with interferon 
From July 1988 onwards, patients were started on maintenance
treatment with interferon alpha, (3 megaunits m–2 3 times a week
s/c) (Schering-Plough, Welwyn Garden City, Herts) following
their recovery from HDM. Initially this took place as part of a
randomized trial, but subsequently interferon maintenance was
instituted in all patients as soon as the WBC count reached 
2 × 109 l–1 and the platelet count 50 × 109 l–1. The dose of interferon
was reduced or stopped according to the full blood count or other
toxic manifestations (Cunningham et al, 1998). 
Evaluation of toxicity 
Toxicity was assessed according to the WHO criteria (Miller et al,
1981). The variables analysed for TT were recovery of neutrophils
to > 0.5 × 109 l–1, recovery of platelets to > 50 × 109 l–1, days of
hospitalization, incidence of serum creatinine being > 177 µ mol l–1
(corresponding to stage B Durie–Salmon) during hospitalization,
mucositis, diarrhoea, hepatic toxicity (bilirubin, transaminases,
alkaline phosphatase) and microbiologically documented infection
(DI). WHO grade III infections (moderate) are defined as febrile
neutropenia with pyrexia > 40˚C unresponsive to antibiotic and
antifungal therapy. WHO grade IV infections (severe) are
neutropenic fevers associated with hypotension. Toxicity 
was attributed to HDM if it occurred during the patient’s hospital-
ization for the transplant or the first 60 days following the 
transplant. 
Transplant-related death was defined as death occurring during
the first 60 days post autograft not related to disease relapse. 
Evaluation of response 
The response in this group of patients has been evaluated pre-
HDM as well as 3 and 6 months post HDM. Our response criteria
and definition of complete remission (CR) have been described
earlier by Gore et al (1989). Briefly, four criteria needed to be met
together for a patient to be regarded as having achieved CR: (1) no
measurable paraprotein on scanning densitometry of serum
proteins separated electrophoretically on a cellulose acetate
membrane and stained with ponceau S; (2) no detectable urinary
Bence–Jones protein on electrophoresis of neat urine stained with
colloidal gold; (3) no more than 5% plasma cells of normal
morphology on the bone marrow aspirate and a normal bone
marrow trephine biopsy; (4) stable skeletal appearances; (5)
criteria 1–4 fulfilled for at least 3 consecutive months. Patients
were regarded as having achieved a partial response (PR) if there
was a 50% decrease in measurable paraprotein (IgG or IgA
myeloma) or bone marrow infiltration (in the case of non-
secretory or Bence–Jones myelomas) which was sustained for at
least a month or more. Relapse was defined as either the reappear-
ance of the paraprotein on 2 samples taken one month apart (or a
25% increase in paraprotein for patients in PR), bone marrow infil-
tration with more than 5% abnormal plasma cells, or development
of new osteolytic lesions (or progression of old lesions). No
response (NR) was considered to have occurred if patients failed
to achieve a CR or a PR or had progression of disease (PD).
Patients were considered to be in continued complete remission
(CCR) or continued partial remission (CPR) if the CR/PR status
attained after the induction infusional chemotherapy (IC)
continued post HDM. Maximum response to IC was defined as
either attainment of CR or a plateau phase for patients in PR
(maximum reduction of the myeloma response criteria parame-
ters). Patients were restaged on day 15 of the second and the fourth
cycle of IC and if they fulfilled the above mentioned response
criteria for restaging without the proviso of 3 months duration,
they were said to have attained CR, PR or NR. The entry into the
prospectively maintained database was done after the three months
duration criterion was fulfilled and this was used for analysis. 
326 B Sirohi et al
British Journal of Cancer (2001) 85(3), 325–332 © 2001 Cancer Research CampaignStatistical analysis 
Patient characteristics were obtained at presentation and at 
high-dose therapy. Values of the characteristics were compared
between groups of patients using non-parametric methods
(Mann–Whitney or Kruskal–Wallis) for continuous numerical data
or the Chi square test for categorical data. All probabilities were 2-
tailed. 
Outcome from the start of HDM was examined using overall
survival (OS) and event-free survival (EFS) plots constructed via
the Kaplan–Meier method (1952). Comparisons between such
plots for different patient groups representing different categories
of a given characteristic (i.e. univariate analysis) were compared
via the log rank test (Peto et al, 1977). The event-points for the
survival curves were death due to any cause for OS and
relapse/death for EFS. 
The categories chosen to represent the univariate influence 
of the continuous variables were based on partition values 
derived from either (a) median values or (b) single or multi-
partition values chosen for optimum influence. These 2 types 
of partitioning (optimal cut-off) were also used for the multivariate
analysis. The optimum values for (b) were found by using 
recursive partitioning which compared P values, produced via log-
rank comparisons on Kaplan–Meier plots, with different parti-
tioning values for the variable being studied (LeBlanc and
Crowley 1993). 
Multivariate analyses of the relationship between outcome and
several variables were performed using forward stepwise re-
gression by the Cox method (Cox, 1972; BMDP software package
1992). The forward stepwise method allows all variables to be
considered for inclusion in the model but, in each step, selects 
the single variable that produces the largest, significant improve-
ment of fit of the model (i.e. has the lowest P value). Successive
steps of single selections from the pool of remaining variables 
are carried out until the improvement in P value is no longer
significant (defined as P > 0.05). This procedure is preferable 
to the pre-selection of eligible variables on the basis of 
univariate  P values because it allows for interrelationships
between variables that may change their significance as the model
develops. 
The pre-autograft variables chosen to be included in the
multivariate analysis were previously found to influence prog-
nosis in patients with myeloma. They were age, serum
calcium, β 2M, serum albumin, Hb, immunologic subtype of
myeloma (IgG vs IgA vs light-chain/IgM/IgD/non-secretory),
presence or absence of Bence–Jones proteinuria, type of light
chain (kappa vs lambda), GFR (model run for GFR as dichoto-
mous N/L value and as a continuous variable), type of IC
(VAMP vs. CVAMP/V-CVAMP), type of autograft (marrow vs
PBSC), Durie-Salmon stage of disease (I/II vs III), number of
courses of IC, and response to IC (CR vs PR vs NR; (Merlini 
et al 1980; MRC 1980; Vesole et al, 1996; Sirohi et al,
1999b)). Because the addition of cyclophosphamide to IC and
the number of courses of IC have an impact on CR, these vari-
ables were also included in the analyses (Raje et al, 1997a;
Sirohi et al, 1999b). 
Because the correct interpretation of corrected GFR values
depend on patient age and body surface area, GFR was treated
both as a dichotomous value (normal/abnormal dichotomy) and a
continuous variable in our analysis of the data set. The analyses
were undertaken in March 2000. 
RESULTS 
Patient characteristics 
The patient demography at presentation and at the time of high-
dose therapy is described in Tables 1 and 2. Patients with a low
GFR had a higher β 2M (P = < 0.0001), calcium (P = 0.009) 
and creatinine (P = 0.0001) and more commonly showed
Durie–Salmon stage IIIA/B disease (P < 0.0001) and Bence–Jones
proteinuria (P = 0.002) at presentation. At the time of high-dose,
they had a significantly higher β 2M (P = 0.02), creatinine 
(P = 0.0006) and stage IIIA/B disease (P = 0.0002). 
Induction treatment 
The median number of courses of IC was 5 (range, 1–9). There
was no difference in the type of IC received by the low and normal
GFR group but patients in the low GFR group received signifi-
cantly more courses (P = 0.001, Table 2). 
GFR 
The median GFR in the whole group of 145 patients was 87
(range, 24–140) ml min–1 1.73 m–2. 38 (26.2%) patients had a GFR
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Table 1 Patient characteristics at presentation 
Normal GFR  Low GFR  P valuea
n = 107 (%) n = 38 (%)
Age–median 51 years (range, 30–72) 
< 51 51 (48) 18 (47) 0.98 
≥ 51 56 (52) 20 (53) 
Sex 
Male 71 (66) 25 (66) 0.9 
Female 36 (34) 13 (34) 
Subtype 
IgG 66 (62) 23 (60) 
IgA 13 (12) 6 (16) 
IgM 3 (3) 0 
IgD 2 (1) 0 0.8 
BJ 18 (17) 8 (21) 
NS 5 (5) 1 (3) 
Light chain 
kappa 62 (58) 27 (71) 0.16 
lambda 40 (37) 10 (26) 
Bence–Jones 
Positive 52 (49) 30 (79) 0.001 
Negative 55 (51) 8 (21) 
Calcium – median 2.39 mmol l–1 (range, 1.75–4.26) 
< 2.39 60 (56) 12 (32) 0.009 
≥ 2.39 47 (44) 26 (68) 
β 2M – median 2.9 mg dl–1 (range, 0.1–48.6) 
< 2.9 65 (61) 6 (16) <0.0001 
≥ 2.9 42 (39) 32 (84) 
Albumin – median 36 mmol l–1 (range, 16–51) 
< 36 49 (46) 22 (58) 0.20 
≥ 36 58 (54) 16 (42) 
Creatinine median 87 µ mol l–1 (range, 56–572) 
<87 63 (59) 8 (21) 0.0001 
≥ 87 44 (81) 30 (79) 
Dure–Salmon stage 
IA/IIA 38 (36) 2 (5) <0.0001 
IIIA/B 64/5 (64) 25/11 (95) 
aChi square without Yates correction below the normal range just prior to HDM. 3 patients had GFR 
< 40 ml min–1 m–2 (20, 24 and 38 ml min–1 m–2). 
Transplant-related toxicity 
Haematological recovery 
The median number of days to neutrophil recovery above 
0.5 × 109 l–1 was the same in patients with low and normal GFR
(20 days, P = 0.7). Recovery of platelets to > 50 × 109 l–1 was also
comparable between the groups, patients with a low GFR
requiring a median of 27 days and those with a normal GFR a
median of 29 days (P = 0.89). 
Organ dysfunction 
Table 3 summarizes the major transplant-related toxicities. Most
patients experienced some degree of mucositis, diarrhoea, nausea,
vomiting and fever. The incidence of oral mucositis (P < 0.0001)
and diarrhoea (P = 0.005) was significantly higher in patients with
low GFR. Hepatotoxicity was negligible in both groups. Grade
III/IV infections were significantly more frequent in the patients
with low GFR (P = 0.04). The incidence of serum creatinine > 177
µ mol l–1 (equivalent to the cut-off used to define Durie–Salmon
stage B) during the first 60 days after HDM was 11% in patients
with a low GFR pre HDM vs. 7% in patients with a normal GFR
(P = 0.43). 
Period of hospitalization 
The median number of days to discharge in patients with a normal
GFR was 23 days compared to 22 days in patients with a low GFR
(P = 0.82). None of the patients required dialysis during their
transplant. 
Transplant-related mortality 
6 (4%) patients died during the autograft, 2 with low GFR (one
died of pseudomonal and staphylococcal septicaemia, the other 
of pulmonary aspergillosis) and 4 with normal GFR group 
(3 neutropenic sepsis and 1 veno-occlusive disease; P = 0.69). 
Response 
The response after IC and HDM is shown in Table 4. Before
HDM, 29 (20%) patients were in CR, 92 (63%) in PR and 24
(17%) were NR. All 29 patients in CR prior to HDM continued to
be in CR after HD. A further 55 (38%) went into CR during HDM
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Table 2 Patient characteristics at the time of HDM 200 mg/m2
Normal GFR  Low GFR P valuea Optimum valueb Number (%)
n = 107 (%) n = 38 (%) n = 145 
Median age 52 years, (range, 31–72) 
<52 51 (48) 18 (47) 0.96 <56 97 (67) 
≥ 52 56 (52) 20 (53) ≥ 56 48 (33) 
Median calcium 2.3 mmol l–1 (range, 1.66–2.73) 
<2.3 51 (48) 18 (47) 0.98 Same as median 
≥ 2.3 56 (52) 20 (53) 
Median β 2 M 2.4 mg dl–1 (range, 1–8) 
<2.4 58 (54) 12 (32) 0.023 <1.8 31 (21) 
≥ 2.4 47 (44) 24 (63) 1.8–3.4 92 (64) 
>3.4 18 (12) 
Missing values 2 (2) 2 (5) 4 (3) 
Median albumin 41 mmol l–1 (range 26–100) 
<41 45 (42) 17 (45) 0.77 ≤ 34 18 (13) 
≥ 41 62 (58) 21 (55) >34 127 (87) 
Median creatinine 78 µ mol l–1 (range, 50–182) 
<78 60 (56) 9 (23) 0.0006 Same as median 
≥ 78 47 (44) 29 (77) 
Stage 
IA/IIA 38 (36) 2 (5) 0.0002 
IIIA/IIIB 68/1 (64) 36/0 (95) 
HDT 
Marrow 52 (49) 18 (47) 0.86 
PBSC 55 (51) 20 (53) 
VAMP type 
VAMP 20 (19) 7 (18) 0.95 
CVAMPc 86 (80) 31 (82) 
None 1(1) 
Courses of IC 
<5 41 (38) 4 (11) 0.001 
≥ 5 65 (61) 34 (89) 
Median GFR 87 ml/min/m2 (range, 24–140) 
<87 33 (31) 38 (100) < 80 52 (36) 
≥ 87 74 (69) 0 80–100 53 (37) 
>100 27 (27) 
a2 × 2 Chi squared test without Yates correction. bOptimum cut-off values obtained after recursive partitioning as described in the text. cAlso includes VCVAMP.so that the total CR rate after HDM was 58% (84/145). The disease
status after HDT was not significantly different between the
groups. 
Survival and relapse 
The median OS was 5.1 years (95% CI 2.5 to 6.2) for patients with
a low GFR vs. 7.5 years (95% CI 5.5 to 12.2) in patients with a
normal GFR (P = 0.015, Figure 1) and the median EFS was 2.1
years (95% CI 1.1 to 3.9) for patients with a low GFR vs. 2.6 years
(95% CI 2.1 to 3.7) for patients with a normal GFR (P = 0.24,
Figure 2). 
There was no statistically significant difference in OS (P = 0.47)
and EFS (P = 0.08) in patients receiving either autologous bone
marrow or peripheral stem cell rescue. 
In the low GFR group, 22/38 patients (58%) relapsed at a
median of 2.8 years (range, 0.2 to 5.9), compared to 53/107 (49%)
at a median of 4.1 years (range, 0.4 to 7.1, P = 0.16) in the group
with a normal GFR. Importantly, the median OS after relapse in
the 22 patients with a low GFR at the time of HDT was only 0.85
years (range, 0.02 to 5.5) compared to 3.4 years (range, 0.14 to
6.7) in the 53 patients with a normal GFR (P = 0.02, Figure 3). 
The median serum creatinine of patients in the low GFR group
at relapse was 96 (range, 58–141) compared to 82 (range, 52–728)
in the low GFR group (P = 0.004), and there was no significant
difference in the intensity of treatment given to these patients after
relapse between the 2 groups. 31/53 (59%) in the normal GFR
group compared to 9/22 (41%) in the low GFR group received
infusional chemotherapy followed by a second high-dose therapy
(P = 0.16). At the time of second high-dose therapy, 5/31 (16%)
vs. 4/9 (44%) respectively had a low GFR (P = 0.07). 
The multivariate analysis was carried out using partitioning in
the way described above. To be consistent with our previously
published data and to have an even distribution of patients, we
have used medians for the continuous variables and the categorical
variables were taken as described above. 
(a) Patients with a normal GFR and in CR before HDM had a
significantly longer OS and achieving CR before HDM was
also predictive of longer EFS (Table 5a) 
(b) Younger patients (age < 56 years) with a low β 2M (< 1.8
better than 1.8–3.4 which in turn is better than > 3.4) had
prolonged OS while those with a higher albumin (> 34) and a
better response prior to HDM (CR better than PR which is
better than NR) had a significantly prolonged EFS (Table 5b). 
Recursive partitioning showed what appeared to be a strong
influence of values away from the median. This is likely to be
spurious since at cut-off points away from median, one arm in the
Kaplan–Meier plot may contain only few patients. In such small
samples, the existence of atypical patients in one arm may produce
a large but atypical effect, but a large number of events in these
groups will have prognostic significance. 
DISCUSSION 
The staging of myeloma patients with respect to their degree of
renal impairment is commonly based on serum creatinine
measurements (Durie and Salmon, 1975). However, serum creati-
nine levels do not increase unless a significant drop in GFR has
already occurred and GFR is considered to be more accurate as a
measure of renal function (Britton et al, 1979; Labeeuw et al,
1994; Kasiska and Keane, 1996; Toto et al, 1997). The clinical
data available in the literature relating to high-dose chemotherapy
in myeloma patients with renal impairment is limited. In the past,
myeloma patients with diminished renal function in our unit
received high-dose busulphan (Mansi et al, 1991). However,
patients receiving high-dose busulphan as well as those receiving
high-dose melphalan at 140 mg m–2 had a significantly worse
progression-free (P = 0.0003) and overall (P < 0.0001) survival
compared with those receiving melphalan 200 mg m–2 (Powles 
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Table 3 Transplant-related toxicity 
Normal Low P valuea
n = 107(%) n = 38(%)
Mucositis 
Grade 0/I/II 82 (77) 11 (29) <0.0001 
III/IV 25 (23) 27 (71) 
Diarrhea 
Grade 0/I/II 90 (84) 23 (61) 0.003 
III/IV 17 (16) 15 (39) 
Creatinine > 177 
Yes 7 (7) 4 (11) 0.43 
No 100 (93) 34 (89) 
Bilirubin 
Grade 0 76 (71) 32 0.24 
I/II 29 (27) 6 
III/IV 2 (2) 0 
Transaminases 
Grade 0 97 (91) 31 (82) 0.21 
I/II 9 (8) 7 (18) 
III/IV 1 (1) 0 
Alkaline phosphatase 
Grade 0 83 (77) 21 (55) 0.01 
I/II 23 (22) 14 (37) 
III/IV 1 (1) 3 (8) 
Infection 
Grade 0/I 6 (5) 0 0.01 
II 79 (74) 20 (53) 
III 18 (17) 15 (39) 
IV 4 (4) 3 (8) 
aChi square without Yates correction. 
Table 4 Response to IC and HDM 200 mg m–2
Normal GFR  Low GFR  P value 
n = 107 (%) n = 38 (%)
Response to IC 
CR 22 (20) 7 (18) 
PR 66 (62) 24 (64) 0.8b
NRa 19 (18) 7 (18) 
Response to 
HDM 
CR+CCR 43+22 (61) 12+7 (50) 0.19b
PR+CPR 5+29 (31) 5+12 (45) 
NR 4 (4) 0 
TRM 4 (4%) 2 (5%) 0.69c
a One patient who did not receive IC is taken as a non-responder. b Chi-
square without Yates correction. c Kaplan–Meier. CR=complete remission;
CCR=continued complete remission; PR=partial remission; CPR=continued
partial remission; NR=non responder; TRM=treatment-related mortality. et al, 1997). This was also demonstrated in a multicentre EBMT
study of autografting in myeloma in which conditioning regimens
that contained HDM were associated with significantly longer
progression-free and overall survival rates (Bjorkstrand et al,
1994). Presently, HDM 200 mg m–2 is probably the most
commonly used regimen in patients with multiple myeloma
(Bjorkstrand et al, 1994; Powles et al, 1997; Barlogie et al, 1999)
and studies with the escalation of the melphalan dose to 220 mg
m–2 are currently being undertaken (Moreau et al, 2000). In 1994,
Kergueris et al reported that adjusting the dose of melphalan
according to renal function was not warranted. Because of the
proven value of HDM in the treatment of myeloma we have
routinely treated myeloma patients with abnormal renal function
with HDM 200 mg m–2 according to a care plan approved by 
the institutional ethics committee. Here we set out to assess the
tolerability and efficacy of this therapeutic strategy. 
Only 3 patients had a GFR < 40 ml min–1 m–2. There was no
difference in neutrophil and platelet recovery between patients with
low or normal GFR. While the potentially increased myelotoxicity
of HDM in patients with low GFR may have been masked by the
stem cell rescue, the presence of renal impairment did not cause any
apparent cytotoxic damage to the autograft by the HDM given 24
hours earlier. This is in keeping with the predominantly non-renal
clearance of melphalan (Kergueris et al, 1994; Tricot et al, 1996) 
Interestingly, however, despite the independence of the area
under the curve (AUC) of melphalan from the GFR, we observed
significantly more mucosal toxicity after HDM in patients with a
low GFR. In their group of 20 patients Tricot et al (1996) observed
that there was a trend towards a longer duration of mucositis in
patients with a creatinine clearance less than 40 ml min–1 who
received HDM 200 mg m–2. Severe mucositis also featured promi-
nently in the French study (Kergueris et al, 1994). It is possible
that independent of the AUC, tissue injury by melphalan is
increased in the presence of uraemia. 
The increased gastrointestinal toxicity of HDM in the presence
of renal impairment may explain the 2.8-fold increase in the inci-
dence and the greater severity of microbiologically documented
infections among our patients with a low GFR. There may have
been a higher rate of bacterial translocation from the gut into the
circulation across damaged mucosa in the low GFR group. Tricot
et al showed that patients with impaired renal function had a
longer duration of fever (P = 0.0005) compared with those with
normal renal function. Nevertheless, unlike in Tricot’s study, in
our cohort of patients the increased risk of infection did not trans-
late into a longer hospital stay. 
The treatment-related mortality was not significantly different
between the 2 groups. Thus, with good supportive care, autotrans-
plants with HDM 200 mg m–2 are safe whatever the renal function,
but patients with a low GFR should possibly receive prophylactic
antibiotics to reduce the transplant-related morbidity associated
with oral mucositis, diarrhoea and infections. 
In the multivariate analysis, the factor that most strongly corre-
lated with a better event free as well as overall survival was CR
immediately before transplantation, confirming previous reports
by ourselves and several other workers (Selby et al, 1988;
Bjorkstrand et al, 1994; Attal et al, 1996; Sirohi et al, 1999b).
Given the importance of achieving CR at the time of high-dose
therapy, intensification of induction treatment may be of benefit,
but consolidation with high-dose intensification in these patients
remains a reasonable approach as the CR rate was increased from
20% to 58% by HDM. Since patients with low GFR required a
higher number of courses of IC to attain maximum response it
appears that they presented with more chemo-resistant disease. 
However, despite the safety of HDM in myeloma patients with
low GFR and their similar EFS to patients with normal GFR, the
long-term outcome of low GFR patients was significantly worse as
patients with a low GFR who relapsed after HDM had a signifi-
cantly shorter OS. The TRM after second line treatment was not
significantly different between the 2 groups (6/53 (11%) died in
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Figure 2 Log-rank comparison of event-free survival (EFS) of patients 
with normal (n = 107) and low GFR (n = 38) post high-dose therapy (HDT); 
P = 0.24 
0123456789 1 0 1 1
Years since relapse
100
80
60
40
20
0
%
 
p
r
o
b
a
b
i
l
i
t
y
 
o
f
 
O
S
 
a
f
t
e
r
 
r
e
l
a
p
s
e
Normal GFR, n = 53
P = 0.023
Low GFR, n=22
Figure 3 Log-rank comparison of overall survival (OS) of patients who
relapsed after autograft in normal GFR (n = 53) and low GFR (n = 22) group;
P = 0.023 
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Figure 1 Log rank comparison of overall survival (OS) of patients with
normal GFR (n = 107) and low GFR (n = 38) post high-dose therapy (HDT).
P = 0.015 the group with normal GFR versus 2/22 (9%) in the low GFR
group; P = 0.78). It is possible that myeloma patients with low
GFR may benefit from more intensive treatment and supportive
care at the time of relapse. 
The multivariate analysis using the variables chosen by recur-
sive partitioning have shown that previously described variables
such as age, β 2M, albumin and disease status prior to HDM
affected the outcome (Sirohi et al, 1999b), further underlining that
the dose of melphalan should not be modified in patients with
abnormal renal function. 
In summary, our experience suggests that the dose of
melphalan need not be reduced in patients with renal failure
receiving HDM. Patients should receive chemotherapy aimed at
increasing the CR rate from the outset, as this is the strongest
prognostic factor for both prolonged OS and EFS. Nevertheless,
patients with abnormal renal function at the time of high-dose
treatment have increased transplant-related morbidity. After
relapse, their prognosis is worse than that of patients whose pre-
transplant GFR is normal and incisive treatment strategies with
optimal supportive care are required for this patient subgroup at
the time of relapse. Our conclusions will need to be confirmed in
a prospective study. 
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